Recent findings have cast a new light on dual antiplatelet therapy (DAPT) in the context of myocardial infarction (MI). For years, the standard protocol for post-MI management has included a prolonged duration of dual antiplatelet therapy—typically around 12 months. However, emerging evidence suggests that a shorter duration of therapy, specifically three months, may offer significant…